Based on this, our target prediction suggested that miR-216a-3p/FKBP5, miR-1188-5p/FKBP5, miR-670-3p/Foxo3, miR-677-5p/RIPK1, miR-802-3p/Smad2 could represent key regulatory axes, and these miRNAs may serve as potential novel therapeutic targets to promote β-cell mass in T2DM. The gene discussed is FOXO3; the disease is type 2 diabetes mellitus.